By Adriano Marchese

Aurora Cannabis' logged a wider loss in its fourth quarter as higher costs offset a rise in revenue.

For the three months ended March 31, the Canadian medical cannabis company posted a net loss from continuing operations of 27.6 million Canadian dollars ($19.8 million), compared with a loss of C$12.1 million in the comparable quarter a year ago.

Aurora said the widened loss was primarily related to other expenses of C$1.7 million in the current period, compared to other income of C$11.9 million in the prior year period.

On an adjusted basis, which strips out exceptional items and one-off costs, earnings fell to a profit C$5.6 million from C$15.3 million.

Total revenue rose to C$84.8 million from C$76.8 million, and came in ahead of expectations which anticipated a slight decline to C$75.7 million.

Aurora said that growth over the prior year was mainly due to a 14% growth in the global medical cannabis business as well as higher wholesale bulk cannabis net revenue.

Meanwhile, consumer cannabis was softer in the period, declining by more than half from the year-prior.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

June 11, 2026 08:08 ET (12:08 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.